Contact Information: Email: email@example.com; phone #: 607-253-3877
Grant Number: 2R01GM068935-05A1
Title: Dynamic Properties of a Glutamate Binding Domain
Annual Direct Cost: $190,000
Project Period: 06/01/10-05/31/15
DESCRIPTION (provided by applicant): Ionotropic glutamate receptors control a wide variety of normal neuronal processes including learning and memory. Activation of these neurotransmitter receptors is involved in a number of neurodegenerative diseases, notably stroke and epilepsy. Analysis of the transmembrane topology has led to the realization that each subunit is made of a series of modules. The module that binds glutamate can be produced in bacteria as a soluble protein (S1S2 domain) and its structure has been determined. The S1S2 domain of AMPA receptors binds agonists and antagonists with approximately the same affinity as the intact receptor and serves as an excellent system for studying the binding domain. In the previous granting period, backbone and sidechain dynamics were studied with a series of partial agonists bound to GluR2 S1S2 using NMR spectroscopy. These measurements, with studies of solution structure, new crystal structures, and isothermal titration calorimetry (ITC), have shed light on the mechanism of agonist and antagonist binding and the relationship between dynamics of the binding domain and channel gating. Based on the results, the relationship between dynamics and channel gating can be approached on a more quantitative level, using mutagenesis designed to modify large-scale lobe motions and backbone motions that correlate with agonist efficacy. In particular, the mechanism by which conformational changes in the S1S2 domain lead to channel activation will be investigated. Because glutamate receptors are thought to function as dimers of dimers, an appropriate model for the activated channel would be the dimer of the S1S2 domain. The protein is monomeric below 6 mM, but the L483Y mutation results in dimeric protein at much lower concentrations. This mutation blocks desensitization in the intact protein, and desensitization is correlated with the dissociation of the dimer interface. Preliminary studies indicate that dimerization leads to changes in the agonist binding site, and the goal will be to determine the effects of dimerization on dynamics and thermodynamics of agonist and antagonist binding. Differences between the dimeric and monomeric states should provide clues as to how the protein changes upon desensitization. Finally, allosteric activators will be studied. These drugs enhance cognition and are being tested in neurological disorders such as Alzheimer's disease. NMR spectroscopy, X-ray crystallography, radioligand binding, and ITC will be used to determine the mechanisms of binding and important interactions with the receptor for a series of activators with differing interactions with the binding domain. These studies will use a range of biophysical techniques with whole cell and patch clamp recording of receptor function to study the agonist and allosteric activator binding sites on the GluR2 AMPA receptor. The results will shed light on the correlation of structure, function and dynamics of an important glutamate receptor subunit and provide essential information for development of drugs that are antagonists or allosteric activators.
PUBLIC HEALTH RELEVANCE: AMPA receptors mediate the majority of fast excitatory synaptic transmission in the central nervous system. Over-activity of these receptors has been implicated in contributing to the pathological effects of stroke and epilepsy, and enhancement of the activity of AMPA receptors has been shown to be beneficial in increasing cognition. For this reason, both agonists and activators of these receptors are likely to be very important therapeutically. Drugs targeted to specific subtypes and splice variants have the potential for more selective action with possibly fewer side effects. The goal of these studies is to understand the structure, function and dynamics of one of the most prevalent and medically relevant AMPA receptors (GluR2), and to provide the groundwork for the development of new therapeutic agents.